LifePoint to start clinical trials for Impact system:
This article was originally published in Clinica
LifePoint is set to begin a US and Canadian multicentre clinical trials of its rapid, saliva-based drugs-of-abuse/alcohol Impact test system. The test, which the company claims is the only product of its kind that can perform alcohol and drug testing simultaneously, detectS markers in saliva and correlates them to equivalent levels in blood. Data generated from the trial will form the basis of the Ontario, California company's 510(k) marketing application to the FDA.
You may also be interested in...
Diagnostics company Bodysphere had to retract an announcement that it had received an emergency use authorization from the US FDA for a COVID-19 serologic test. See why Bethany Hills, an attorney with law firm Morrison & Foerster, says this may be a cautionary tale for other manufacturers.
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Japanese ICT giant applies novel advanced computing techniques with a US venture partner to more rapidly identify lead molecules from a huge virtual space.